PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of currneuroLink to Publisher's site
 
Curr Neuropharmacol. 2009 September; 7(3): 195–206.
PMCID: PMC2769003

Adenosine A2A Receptors in Psychopharmacology: Modulators of Behavior, Mood and Cognition

Abstract

The adenosine A2A receptor (A2AR) is in the center of a neuromodulatory network affecting a wide range of neuropsychiatric functions by interacting with and integrating several neurotransmitter systems, especially dopaminergic and glutamatergic neurotransmission. These interactions and integrations occur at multiple levels, including (1) direct receptor- receptor cross-talk at the cell membrane, (2) intracellular second messenger systems, (3) trans-synaptic actions via striatal collaterals or interneurons in the striatum, (4) and interactions at the network level of the basal ganglia. Consequently, A2ARs constitute a novel target to modulate various psychiatric conditions. In the present review we will first summarize the molecular interaction of adenosine receptors with other neurotransmitter systems and then discuss the potential applications of A2AR agonists and antagonists in physiological and pathophysiological conditions, such as psychostimulant action, drug addiction, anxiety, depression, schizophrenia and learning and memory.

Key Words: Adenosine, A2A receptor, caffeine, psychostimulant, amphetamine, cocaine, schizophrenia, anxiety, depression, dopamine, glutamate.

INTRODUCTION

Behavior, mood and cognition were previously considered to be mainly controlled by dopaminergic and glutamatergic neurotransmission. The ability of the adenosinergic system to modify these behaviors and cognitive function has attracted a great deal of attention as increasing evidences support the tight relationship between adenosine-based modulation and the dopaminergic and glutamatergic systems. Adenosine is ubiquitously distributed throughout the central nervous system (CNS). While early research pointed to the role of adenosine as a metabolite of adenosine triphosphate (ATP) and cyclic adenosine monophosphate (cAMP), the importance of this molecule is now widely recognized as a modulator of neurotransmission and complex behaviors. Indeed, adenosine fulfills two important roles: (1) as a homeostatic transcellular messenger in all cells; (2) and particularly as a neuromodulator controlling neurotransmitter release and neuronal excitability [31, 63].

Endogenous extracellular adenosine, acting mainly through adenosine A1 and A2A receptors (A1Rs and A2ARs) in the CNS, controls and integrates a wide range of brain functions, most notably regulation of sleep, locomotion, anxiety, cognition and memory [47, 63, 64]. Consequently, dysfunction of adenosinergic signaling is implicated in pathologies ranging from epilepsy to neurodegenerative disorders to psychiatric conditions [175]. Owning to adenosine’s unique role of integrating glutamatergic and dopaminergic neurotransmission systems, adenosine-based therapies are rapidly evolving in preclinical and clinical studies for the treatment of different neurological disorders [62] and the adenosinergic system is increasingly recognized as a potential target for the development of new therapies for psychiatric disorders [32, 34].

The distribution, molecular structure and function of A2ARs in the brain, has extensively been reviewed elsewhere [22, 32, 63, 65]. Briefly, the A2AR belongs to the G-protein coupled adenosine receptor family and is highly expressed in the striatum [61, 182]. A2ARs are also expressed at lower levels in other brain areas, including hippocampus, cerebral cortex, nucleus tractus solitarius, motor nerve terminals and glial cells. Activation of A2ARs enhances the release of several neurotransmitters, such as acetylcholine, glutamate and dopamine, but inhibits gamma aminobutyric acid (GABA) release [24, 36, 47, 109]. A2AR activation also modulates neuronal excitability and synaptic plasticity, and affects various behaviors including locomotor activity, sleep-wake cycle, anxiety, depression and learning and memory. At the cellular level, A2ARs are localized predominantly in the soma of GABAergic (enkephalin-containing, dopamine D2 receptor-expressing) striato-pallidal projection neurons and to a lesser extent in asymmetrical excitatory synapses at the dendrites of cortico-striatal terminals [7, 61, 163, 182, 203]. At the molecular level, the A2AR has been shown to interact with other neurotransmitters and neuromodulator receptors (possibly through molecular dimerization), including dopamine D2 receptor (D2R), adenosine A1 receptor (A1R), cannabinoid CB1 receptor (CB1R), metabotropic glutamate receptor subtype 5 (mGluR5) and facilitatory nicotinic acetylcholine (Ach) receptor. These interactions expand the range of possibilities used by adenosine to interfere with neuronal function and communication [47, 57, 59, 181].

In the present overview, we mainly recapitulate some molecular features of brain A2ARs and the ability of the A2AR to integrate several neurotransmission and signaling pathways that might be relevant to the potential therapeutic interest of psychopharmacology, particularly in psychostimulation, drug addiction, anxiety, depression, psychiatric disorder, e.g. schizophrenia, and in learning and memory [185].

MOLECULAR BASIS FOR A2AR MODULATION OF OTHER NEUROTRANSMITTER SYSTEMS IN THE BRAIN

A2ARs are highly expressed in the striatum, a pivotal locus with high levels of neurotransmission and neurotransmitter receptors, thus providing an anatomical basis for the interaction between the A2AR and other, such as dopaminergic and glutamatergic, neurotransmitter systems. These interactions occur at multiple levels, including (1) direct receptor-receptor cross-talk at the cell membrane, (2) intracellular second messenger systems, (3) trans-synaptic actions via striatal collaterals or interneurons in the striatum, (4) and interactions at the network level of the basal ganglia. Compared to other relatively “circumlocutory” interactions, the intramembrane receptor-receptor interactions are more direct in spacial connection. Agnati and Fuxe first reported experimental observations for the existence of membrane receptor-receptor interaction [1, 70, 221]. Since then, the concept has been further developed to receptor-receptor heteromers and the so called “receptor mosaic” with the discovery of aggregates of multiple receptors [67, 71]. The interactions involving the A2ARs have been described for several G-protein coupled receptors, including D2Rs, A1Rs, CB1R and mGluR5 [54, 181]. The largely antagonistic and occasionally synergistic interactions between the A2AR and other receptors occurring directly between receptor complexes have been documented.

1. Interaction Between Adenosine A2ARs and A1Rs

The prevalent neuromodulatory influence of adenosine is inhibitory on neuronal activity in the brain [63]. Adenosine is known to modulate the release of many neurotransmitters, including dopamine, glutamate, GABA, serotonin, noradrenaline and ACh, though the inhibition of excitatory neurotransmitters (e.g. glutamate) is most pronounced [31, 47, 66]. Adenosine modulation of neurotransmitter release is mediated through the activation of the A1R and A2AR. Adenosine activation of Gi-coupled A1Rs reduces neurotransmitter release at pre-synaptic nerve terminals and depresses neuronal firing at postsynaptic sites [66, 121, 194]. In contrast, adenosine activation of the Gs/olf-coupled A2AR has been demonstrated to exert an excitatory modulation on the neurotransmitter release of glutamate and ACh in the striatum, and ACh in the hippocampus [33, 110]. The A2AR also controls GABA release in the striatum [108] as well as in the hippocampus [185]. Additionally, the activation A2AR decreases the functionality of the A1R in some experimental settings [46, 130, 131, 155].

A1Rs and A2ARs may be activated under different conditions; adenosine may preferentially act at A1Rs under basal condition, probably due to its relatively high expression level and wide-spread distribution in the brain [31, 63]. However, the different affinities of adenosine for A1Rs and A2ARs is still an open issue [35, 47]. It has been suggested that A1Rs largely maintain tonic homoeostatic adenosine functions whereas A2ARs mostly exert its fine-tuning modulation under some pathophysiological situations [170, 186]. Such receptor discrimination may be achieved through the pattern of neuronal firing (i.e. with high neuronal discharge, there may be higher levels of ATP and adenosine in the synapse), the different sources of adenosine (i.e. intra- and extracellular formation), the localization of relevant synthetic or metabolic enzymes, or the relative position of adenosine release and receptor sites (synaptically versus extra-synaptically) [35, 94, 174, 184]. Furthermore, the partially overlapping distributions of these two adenosine receptors may also permit local formation of heteromers to exert their opposite modulating effects directly via a so called "concentration-dependent switch" mechanism [54].

2. Interaction Between Adenosine A2ARs and Dopamine D2Rs

Striatal A1Rs and A2ARs are major neuromodulator receptors that exert profound effects on D1Rs- and D2R-mediated dopamine signalling and function in the striatum. Evidence suggests the existence of antagonistic A1R-D1R heteromeric receptor complexes in the basal ganglia and prefrontal cortex, particularly in the direct striatonigral GABA pathways. The antagonistic A1R-D1R interactions at the neurochemical and behavioral levels can be explained in part by the existence of such A1R-D1R heteromeric receptor complexes and by antagonistic interactions at the level of the second messengers. On the other hand, A2AR-D2R heteromers have been demonstrated as the first example of epitope-epitope electrostatic interactions underlying receptor heteromerization [55]. A large number of studies with different techniques, i.e. coimmunoprecipitation, fluorescence resonance energy transfer (FRET), bioluminescence resonance energy transfer (BRET), biochemical binding and signaling, microdialysis and behavioral pharmacology have indicated the existence of A2AR-D2R heterodimers in the striato-pallidal GABA neurons, where activation of A2ARs reduces binding, coupling and signaling of D2Rs [18, 23, 52, 91, 207]. However, since supporting evidence from in vivo co-immunoprecipitation studies could be subjected to other interpretations, the evidence of A2AR-D2R dimmers in intact brain tissues is still not clear yet. Further studies are needed to conclusively demonstrate the functional significance of receptor heterodimer in vivo.

The antagonistic A2AR-D2R interactions in brain have also been demonstrated at the second messenger levels [146, 183, 199], through which the A2AR strongly modulates the excitability in the striato-pallidal GABA neurons probably via its ability to counteract D2R signaling to multiple effectors. For example, the activation of the A2AR can counter the D2R-induced inhibition of the Ca2+ influx over the L-type voltage-dependent Ca2+ channels (CAV 3.1 channels) via the activation of phospholipase C and protein phosphatase-2B [54, 90]. The counteraction of this cascade by A2ARs may involve Go and/or Gq11 protein with release of the βγ subunits, and leads to increased phosphorylation of CAV3.1 channels and favoring an upstate of the striatal neuronal firing [200]. Furthermore, the D2R-induced reduction of firing rates in the dopamine-denervated striatum is enhanced by A2AR antagonists and attenuated by A2AR agonists [199]. There also exists a reciprocal interaction between A2AR-D2R receptors, through which the activation of D2Rs can inhibit the A2AR-induced increase in cAMP accumulation via Gi/o at the level of adenylate cyclases [54, 69, 114].

3. Interaction Between Adenosine A2ARs and Dopamine D1Rs

Pharmacological studies have revealed functional interaction between A2AR and D1R [144, 145, 162, 163]. At the systemic level, pharmacological blockade of A2AR potentiates D1R agonist-induced rotational behavior [145] and c-fos expression in dopamine-depleted striatum [162]. The modulation of phosphorylation on neuronal dopamine and cAMP-regulated phosphoprotein 32 (DARRP-32) by the interaction of A2AR and D1R has been investigated in brain slices and intact animals [85, 205]. DARPP-32 is expressed in the medium spiny neurons of both the direct and indirect pathways. Stimulation of D1Rs and A2ARs or blockade of D2Rs increases DARPP-32 phosphorylation in distinct cell populations of the striatum [204]. Blockade of A2ARs or stimulation of D2Rs not only abolishes D2R antagonist- or A2AR agonist-induced DARPP-32 phosphorylation, but also antagonizes the D1R agonist-induced DARPP-32 phosphorylation in the striatum [201]. Furthermore, tetrodotoxin (TTX) blocks this A2AR-D1R interaction, suggesting a trans-synaptic (network) cross-talk between A2ARs and D1Rs [127]. Importantly, DARRP-32 can integrate two distinct pathways, adenosine and dopamine signaling, thus providing a possible molecular explanation for the long-known behavioral interaction between A2ARs and D1Rs [63]. Lindskog et al. (2002) suggested that DARPP-32 is required for A2AR inhibition-induced persistent motor stimulation since caffeine-induced motor activity is greatly reduced in DARPP-32 knockout mice [128]. At the molecular level, caffeine treatment reduces phosphorylation of DARPP-32 at the Thr34 site by blocking A2ARs [201]. Conversely, caffeine increases phosphorylation of DARPP-32 at the Thr75 site via an inhibitory feedback loop of protein kinase A (PKA), which leads to further reduction of PKA activity through feedback inhibition [14, 128, 152]. Thus, DARPP-32 appears to be an important molecular target for integration of adenosine and dopamine signaling through phosphorylation at Thr34 and Thr75 sites.

Recently, a genetic study of drug addiction showed that D1R-A2AR double knockout mice shared phenotypic similarities of some behavioral components with A2AR knockout mice or the mice with sole deficiency of D1Rs in terms of preference for ethanol and saccharin; whereas other components of behavioral phenotypes in the D1R-A2AR double knockouts were likely attributable to the loss of both receptors [191]. These data suggest an interaction of D1Rs and A2ARs in the reinforcement processes underlying the intake of rewarding substances. In addition, there is limited evidence for the interaction of A2AR and D3R [210].

4. Interaction Between A2ARs and Glutamatergic Neurotransmission

Glutamate is the main excitatory neurotransmission in the CNS. Glutamate activates either ionotropic receptors (including NMDAR, AMPAR and kainate-type receptor) that are mostly localized in the postsynaptic density [12] or G protein-coupled metabotropic glutamate receptors (mGluRs) that are mostly localized extrasynaptically [209]. A2ARs interact with glutamatergic system at several levels in the brain. First, ultrastructural findings suggest that extra-striatal A2ARs are mostly synaptically-located [171], particularly in glutamatergic synapses [173]. These presynaptic A2ARs have been demonstrated to control the release of glutamate in the striatum, cerebral cortex and hippocampus [24, 130, 134, 164] and NMDAR activity in the striatum [172]. Second, it has been reported that A2ARs may indirectly control the level of extracellular glutamate by modulating the activity of glutamate transporter in astrocytes [72, 154].

Third, the receptor heterodimer mechanism is also suggested to underline the interaction of A2AR and the glutamatergic system, particularly with mGluR. The immunoreactivities of A2AR and mGluR5 were found to be colocalized in primary cultures of striatal neurons [68] as well as in striatal glutamate nerve terminals [177]. Furthermore, coimmunoprecipitation studies suggest that the existence of possible heteromeric receptor complexes containing A2AR and mGluR5, where synergism may occur between A2AR and mGluR5 [57]. This heteromeric receptor complex is believed to underlie the finding that agonists of A2AR and group I mGluR could synergistically reduce the affinity of D2R agonist binding sites in striatal membranes [58].

Fourth, concurrent stimulation of A2AR and mGluR5 results in synergistic interactions at the level of c-fos expression and phosphorylation of extracellular signal-regulated kinases (ERK) and DARPP-32 in the striatum [57, 153]. Combined A2AR and mGluR5 activation have also led to synergistic cellular effects on GABA release in the ventral striato-pallidal GABA neurons [44]. Recently, Coccurello et al. (2004) first demonstrated a synergism between A2AR and mGluR5 in the control of locomotion [25], which provides a direct functional link between A2AR and the glutamatergic system and also strengthens the A2AR as potential target to modulate psychostimulant effects. In addition, a study from Schwarzschild’s group (2005) demonstrated that co-administration of the selective mGluR5 antagonist MPEP and selective A2AR antagonist KW-6002 exerts synergistic locomotor stimulation in both normal and Parkinsonian mice [98]. The dependence of MPEP-induced motor activity on the A2AR and mGlu5R further demonstrates the functional interaction between A2AR and mGluR5 at the behavioral level.

PSYCHIATRIC BEHAVIORAL EFFECTS AND THERAPEUTIC POTENTIAL OF A2AR MANIPULATION IN THE BRAIN

1. Psychostimulant Effects

A2ARs in medium spiny neurons have been established to be the determinant for the control of motor function, since A2AR ligands produce most significant motor effects [63, 64, 181, 183] that were abolished in mice deficient in A2ARs [126]. In fact, A2AR modulation of normal or hyperdopaminergic conditions is relevant to psychopharmacology [117, 118], whereas the A2AR control of the hypodopaminergic condition is directly relevant to Parkinson’s disease (PD) therapy [38, 180]. In dopamine depleted animals, the main mechanism by which A2AR antagonists improve motor activity is proposed to be via modulation of GABA release. Thus, the systemic administration of A2AR antagonists increase motor activity in animals pretreated with D2R antagonists, reserpine, 6-OH-dopamine or after genetic inactivation of D2R [21, 88, 102, 161, 190, 214] or MPTP-treated monkeys [86, 103].

On the other hand, the antagonistic interaction of A2AR-D2R is considered to be the basis for the potential therapy of neuropsychiatric disorders. A2AR agonists inhibit, and A2AR antagonists potentiate the motor, discriminative, and rewarding effects of psychostimulants [60, 89, 97, 111, 160, 165, 176, 189]. The non-selective A1R and A2AR antagonist, caffeine, also potentiates these effects of psychostimulants [26, 73, 74, 143, 147]. Intriguingly, genetic inactivation of global A2AR or A2AR in forebrain neurons has been shown to attenuate acute psychostimulant effects as well as psychostimulant behavioral sensitization [10, 20, 21]. To provide an explanation for the well-known discrepancies - pharmacological blockade and genetic deletion of A2AR potentiates and attenuates, respectively, psychostimulant effects [10, 20, 21, 60], we recently showed that the selective inactivation of striatal A2ARs enhances the psychostimulant effect while inactivation of forebrain (including striatal, cortical and hippocampal) A2ARs attenuate psychostimulant effects. This study suggests that striatal A2AR and extra-striatal A2AR offer opposite modulation, possibly through different effects of pre- and post-synaptic A2ARs in the striatum [188].

Furthermore, a recent coimmunoprecipitation study demonstrates that A2ARs are able to form receptor complexes with CB1R in the rat striatum, where they are colocalized in dendritic processes and possibly nerve terminals [19]. Thus, the function of CB1R is apparently dependent on A2AR activation and modulation of A2ARs may affect the rewarding behavior of cannabinoid [6, 219]. In fact, the finding of A2AR-mediated glutamate release and A2AR-CB1R interaction in the striatum opens up an interesting possibility of A2AR-based psychopharmacological therapy.

2. Drug Addiction

Drugs of abuse have varying mechanisms of actions that create complex behavioral patterns related to drug consumption, drug-seeking, withdrawal and relapse. The extracellular levels of adenosine are elevated upon exposure to drugs of abuse [9] and may modify addiction-related behavior [16]. By acting at the A2AR in the ventral striatum, modulation of A2AR activity may influence the reinforcement processes underlying opiate, ethanol and psychostimulant intake [17].

For example, the facilitative role for the A2AR has been suggested in opiate reward, reinforcement as well as opiate-seeking behavior. The A2AR agonist CGS 21680 increases, while the A2AR antagonist DMPX reduces, morphine self-administration in rats [178]. Recently, using A2AR knockout mice, Soria et al. (2006) showed that A2AR knockout mice display a lower rate of cocaine self-administration, a reduction in the maximal effort to obtain a cocaine infusion, and a vertical shift of the cocaine dose-response curve [196]. This indicates that A2ARs seem to be required to develop the addictive effects of this drug. Furthermore, decreased morphine self-administration, breakpoint and conditioned place preference were also observed in A2AR knockout mice [17], These data support a decrease in motivation of morphine consumption, perhaps reflecting diminished rewarding effects of morphine, in A2AR knockout mice. The mechanism underlying attenuated reward behavior of A2AR knockout mice is not clear, but these findings are consistent with previous studies showing a synergistic rather than an antagonistic D2R-A2AR interaction [16]. Furthermore, a dysregulation of glutamatergic signaling caused by inactivation of presynaptic A2AR could be partially responsible for this phenotype. This is in line with the notion that molecular adaptations of the cortico-accumbens glutamatergic synapses are involved in compulsive drug seeking and relapse.

However, A2AR inactivation may play a differential role in the modulation of psychostimulant effects, depending on the involvement of either striatal A2ARs located on the medium spiny neurons themselves, or A2ARs located on the cortical glutamatergic afferents that synapse on these striatal neurons [188]. On one hand, the activation of A2ARs can positively modulate glutamatergic input to the nucleus accumbens through synergistic interactions with mGluR5, and thus maintain a facilitative role in behavior such as psychomotor sensitization and addictive behavior as described above. Alternatively, through antagonistic interaction with D2Rs, activation of A2ARs can attenuate the rewarding effects of psychostimulant drugs. Indeed, in the study of reinstatement of cocaine-seeking behavior [215], the A2AR antagonist CGS15943 was found to reinstate cocaine-seeking and functions as an intravenous reinforcer, while the A2ARs agonist CGS21680 was found to produce a rightward shift in the CGS15943 reinstatement dose-effect curve. Thus, it remains to be determined whether A2AR influences reward via striatal A2ARs or extra-striatal A2ARs. It is also possible that A2ARs may either directly interact with the reward (i.e. dopamine or opioid) system or indirectly via interaction with other neurotransmitter systems such as glutamate or cannabinoids in the brain.

3. Anxiety

Clinical investigations, pharmacological studies and models of genetically modified rodents have implicated adenosine receptors in the etiology and modulation of various types of anxiety. Caffeine and alcohol have been involved in anxiety-related behavior, due to their antagonism at adenosine receptors and ability to increase adenosine levels, respectively. The adenosine effects on anxiety have been partly attributed to the anxiogenic effects of A1R antagonism. However, there are several lines of evidence indicating the involvement of the A2AR in anxiety. First, spontaneous anxiety-like behavior is enhanced in A2AR knockout mice compared to their WT littermates [13, 15, 122], indicating that adaptive mechanisms in A2AR knockouts may result in increased propensity for anxiety. Second, human genetic association studies indicate the association between A2AR gene polymorphisms and caffeine-induced anxiety [4, 5, 211]. Third, pharmacological studies with caffeine suggest the involvement of adenosine receptor in anxiety-related behavior. It is reported that adenosine has anxiolytic effects, which could be reversed by pretreatment with caffeine and theophylline [113]. Similarly, caffeine and theophylline at higher doses showed anxiogenic effects, suggesting that blockade of adenosine receptors after chronic ingestion of caffeine led to increased anxiety-related behavior. However, it should be noted that caffeine effects on anxiety are dose related: higher doses of caffeine tend to increase [83, 84, 115, 129, 192, 198] and lower doses of caffeine tend to reduce anxiety levels in humans [87, 124, 125]. The dose-dependent effect of caffeine may due to different effects of caffeine on different subtypes of adenosine receptors in anxiety. Fourth, El Yacoubi et al. (2000) also showed that the short-term anxiety-like effect of caffeine in mice might not be related solely to the blockade of A2AR, since it is not shared by A2ARs selective antagonists [50]. Therefore, the role of A2AR in anxiety remains to be defined [27].

4. Depression

The effect of the adenosine modulation on depression is complex due to the participation of several neurotransmission systems, such as dopaminergic and serotoninergic systems as well as the corticotrophin system [34, 75, 96, 179]. The involvement of adenosine in depression has also been supported by other indirect evidence showing that classical tricyclic antidepressants, such as nortriptiline, chlomipramine or desipramine, can bind to adenosine receptors and reduce the activity of ecto-nucleotidases in cortical nerve terminals [41]. Thus, the classical antidepressants also reverse the adenosine-induced immobility [112, 113]. However, the pharmacological effect of adenosine on depression is not clear yet. A series of studies showed that administration of adenosine, either peripherally or intra-cerebroventricularly, has an antidepressant effect, which involves the recruitment of adenosine receptors, the NO-cGMP system, or the opioid system [104-106]. However, other studies found that adenosine and its analogues caused depressant-like behavioral effects by increasing immobilization time in rats submitted to inescapable shocks and forced swim tests [93, 141, 142, 217].

At the receptor level, the blockade of A2ARs relieves the early stress-induced loss of synaptophysin, a synaptic marker, in the hippocampus of rats subjected to sub-chronic restraint stress [30]. A2AR antagonists prolong escape-directed behavior in the tail suspension and forced swim tests [49]. Additionally, A2AR knockout mice displayed an attenuated ‘behavioral despair’ in these two screening tests [48]. The same research group furthermore demonstrated that haloperidol (a D2R antagonist) prevented the antidepressant effects resulting from A2ARs blockade [48, 49]. This evidence suggests a potential role of A2AR modulation as novel anti-depressant target.

However, mechanisms by which the A2AR exerts its modulation of depression are not clear yet, but adenosine modulation of the serotoninergic system may in part be responsible [78]. For example, adenosine receptors have been shown to control the release of serotonin [156]. Furthermore, caffeine, probably via blockade of A2AR, relieves restraint-induced stress, which correlates with reduction of serotonin levels in the hippocampus [218]. Given the increasingly recognized role of neurogenesis and neuronal trophic factors in the depression-related behavior [136, 137], it is interesting to note the novel interaction between A2ARs and Trk-B receptors [95], and neurotrophins, such as brain-derived neurotrophic factor (BDNF) [45, 123], which may provide another potential mechanism for the involvement of A2ARs in anxiety modulation. Thus, beyond interaction with D2Rs, the interaction of the A2AR with other neurotransmitter systems, such as glutamatergic, serotoninergic, and corticotrophin system as well as trophic factors should be examined.

5. Schizophrenia

Schizophrenia is a complex neuropsychiatric disorder characterized by cognitive deficits, and positive and negative symptoms [99, 150]. Almost all antipsychotics currently used in clinical practice are dopamine D2R antagonists, though they produce many side effects. The development of novel pharmacological targets for antipsychotics is still very limited, primarily due to the heterogeneity, lack of solid anatomical or neurochemical basis of the disorder, and lack of an adequate animal model that faithfully mimics the features of behavioral changes found in this psychiatric disorder [28, 51, 100, 101]. To date, many biochemical and neurochemical markers as well as a rather broad brain area have been implicated in the pathogenesis of diverse psychiatric disorders [11, 133, 149, 195, 197]. On the other hand, the current evaluation of the efficacy of novel antipsychotics still largely relies on the alleviation of behavioral changes that characterize schizophrenia.

Recent progress in adenosine neurobiology supports the notion of adenosine-based therapy and the A2AR as a novel therapeutic target for the treatment of psychiatric disorders. The first line of evidence came from pharmacological and genetic studies showing that A2AR activity affects schizophrenia-like behaviors in patients. Caffeine exacerbates positive symptoms [39, 132, 138, 140, 151] of schizophrenia, whereas adenosine transport inhibitors (such as dipyridamole) and xanthine oxidase inhibitors (such as allopurinol) may be beneficial for schizophrenia [2, 3]. Intriguingly, a clinical report suggests that poorly responsive schizophrenic patients improved considerably with add-on of allopurinol [116]. Early studies found that a single-nucleotide polymorphism (SNP) of the A2AR gene was a candidate for a schizophrenia susceptibility gene on chromosome 22q12-13 [42, 92], but this has not been replicated by others. Furthermore, theophylline was shown to mimic deficiency of sensorimotor gating [77], as evaluated by a disturbed prepulse inhibition or P50 evoked potential found in schizophrenic individuals [167]. These observations of clinical genetics warrant further investigation.

Second, the adenosine-hypofunction hypothesis of schizophrenia is further supported by studies from Yee et al. (2007) [220] using a transgenic mouse model with overexpression of adenosine kinase, causing decreased adenosine levels in forebrain. They demonstrated that subtle changes in adenosine levels in forebrain could lead to the emergence of behavioral endophenotypes implicated in schizophrenia and abnormal response to psychostimulants, i.e. amphetamine and MK-801 [220]. It is also reported that startle habituation (a measure of sensorimotor function) was reduced by A2AR antagonists [148] and genetic deletion of A2ARs in mice [213]. The third line of evidence in supporting a role of A2ARs in the pathophysiology of schizophrenia came from observations that treatment with antipsychotic drugs alter the adenosinergic system in animals and in humans [4, 135, 148, 159, 213]. It was also observed that clozapine, an atypical antipsychotic, induced c-fos expression that could be blocked by A2AR antagonists in rodents [159]. In addition, this clozapine-induced antipsychotic effect also affects the ectonucleotidase pathway, thus consequently modulates adenosine levels and resulting activation of A2ARs [119]. In clinical studies, Martini et al. (2006) demonstrated an upregulation of A2AR in platelets from patients under treatment with haloperidol, a typical antipsychotic [135]. This study also revealed the co-expression of A2ARs and D2Rs assembled into heteromeric complexes in human platelets. Conversely, chronic treatment with non-dopamine based atypical antipsychotic was not able to induce any significant alterations in A2AR equilibrium binding parameters and receptor responsiveness. In line with this finding, an upregulation of striatal A2ARs has been demonstrated to occur in schizophrenia patients with antipsychotic treatment [4]. Noticeably, the increased A2AR density correlated with the dose of antipsychotics in chlorpromazine equivalents, which suggests a role of A2ARs in the molecular effects of antipsychotic drugs.

The fourth line of evidence came from molecular studies suggesting a modulatory role of A2ARs as a fine-tuner in re-balancing an impaired glutamatergic-dopaminergic communication. Regarding dopaminergic function, the antagonistic interaction of A2AR-D2R in the striatum suggested anti-psychotic behavior in schizophrenia by A2AR agonist to function as a dopamine receptor antagonist. The activation of A2ARs can reduce D2R affinity and function, which may potentially underlie the antipsychotic-like profile of adenosine agonists [56], the hyperdopaminergic effect of caffeine [53, 56] and the exacerbation of psychotic symptoms by caffeine in schizophrenic patients [132]. More data discussed in other reviews suggested the relationship between hyperdopaminergic transmission and unbalanced adenosinergic modulation in the striatum [82, 120, 187, 202]. These observations support the possibility that the manipulation of A2ARs (by activation of A2AR) may help restore an adequate dopaminergic signaling. Regarding glutamatergic function, A1R and A2AR agonists have both been shown to prevent behavioral and EEG effects induced by NMDAR antagonists [166, 193]. In an NMDAR hypofunction model of schizophrenia [157], the function of NMDARs could be modified by both A1R and A2AR activities [40, 76, 172, 208, 216]. Furthermore, both A1Rs and A2ARs control the evoked release of glutamate in striatum [24, 177]. Conversely, the activation of the NMDAR increases the adenosine tone [139], while inhibition of the NMDAR reduced adenosine release [43]. Importantly, the psychostimulant effects of NMDAR antagonists are largely abolished by genetic inactivation or pharmacological blockade of A2ARs [176, 188]. These studies suggest that modulation of A2ARs may re-balance the hypofunction of NMDARs in models of schizophrenia. As reviewed in the above sections, the existence of heteromeric A2AR-D3R and A2AR-mGluR5 receptor complexes may also strengthen the potential modulation of A2AR on schizophrenia therapy [206].

However, the effect of adenosine modulation on psychiatric disorders is likely more complex, with involvement of different neurotransmitter systems in various brain regions. For example, we recently demonstrated that striatal deletion of A2ARs enhances the actions of psychostimulants, whereas deletion of A2ARs in forebrain (including striatum, cortex and hippocampus) attenuates the effect of psychostimulants. These data suggest that striatal A2ARs and extra-striatal A2ARs exert different effects on psychomotor activity. Thus, adenosine-based psychopharmacological therapy may rely on the status or degree of dysfunction in other neurotransmitters, or spatial targeting of adenosine agonists/antagonists, or drug specificity, selectivity, dosage and paradigm.

6. Learning and Memory

Several recent pharmacological and genetic studies suggest a potential modulatory role of brain A2AR activity on learning, memory, and other cognitive process [34, 181]. For example, local administration of A2AR agonists into the posterior cingulate cortex impaired memory retrieval in rats [158]. Conversely, the A2AR antagonist SCH58261 and caffeine have been shown to improve social recognition memory [169] and improve memory performance in rodents through different tasks [206]. Genetic inactivation of the A2ARs enhanced spatial recognition memory and novelty exploration in Y-maze testing in mice [212]. Recently, two studies demonstrated that both pharmacological blockade and genetic inactivation of A2ARs attenuated β-amyloid-induced memory loss [29, 37]. The above results suggest that the A2AR activity can modify the spatial memory process in rodents.

On the other hand, working memory primarily depends on the integrity of prefrontal cortical function [80] and is critical to human reasoning and judgment, which is at the core of pathophysiology for many neuropsychiatric disorders such as Alzheimer’s disease [8, 107, 126] and schizophrenia [81]. The control of working memory by A2ARs [169] is supported by several elegant behavioral studies showing an impact of caffeine [168]. Recently, transgenic overexpression of A2ARs in cortex has been shown to impair spatial working memory in radial maze, repeated trials of Morris water maze and objective recognition tests [79]. In agreement with this finding, we recently observed (unpublished data) that genetic inactivation of A2ARs significantly improved working memory; furthermore, the improved working memory was selective for this specific short-term memory whereas the performance of spatial reference memory and the memory retention after prolonged training was largely indistinguishable between A2AR knockout mice and their WT littermates. These results suggest a selective modulatory role of A2AR activity in working memory.

CONCLUDING REMARKS

In this review, we have described the role of adenosine A2A receptor-driven interactions with other neurotransmitter systems, at multiple levels of psychopharmacology, from the molecular basis of receptor-receptor cross-talk, to pharmacological and genetic manipulations of A2AR activity, and the alteration of neuropsychiatric phenotypes in psychostimulant addiction, anxiety and depression, schizophrenia and learning and memory. Based on the literature to date, the A2AR is involved in multiple receptor-receptor interactions, multiple neurotransmissions and multiple neuropsychiatric disorders. In particular, it tightly interacts with two main neurotransmitter systems, the dopaminergic and glutamatergic signaling pathways, with implications for a wide range of psychiatric behaviors and several psychiatric disorders. Hence, A2ARs are ideally positioned as a fine-tuner, providing integrated effects between glutamatergic and dopaminergic signaling, and may represent a novel neuropsychopharmacology target.

Despite its attractive therapeutic potential, several concerns need to be introduced, when evaluating the putative role(s) of A2ARs in psychopharmacology. First, since adenosine system works via neuromodulation, the modulatory ability of the adenosine system (including the A2AR) may depend on and may intricately be linked with the activity of other “potent” neurotransmission systems, i.e. dopaminergic, glutamatergic and serotoninergic systems. Second, a primary role of the adenosine neuromodulatory system seems to be maintenance of homeostasis or promotion of the adaptation of multiple neurotransmitter systems in the brain. Thus, adenosine, and A2ARs in particular, seem to curtail extremes (i.e. over-stimulation or under-stimulation) of these neurotransmitter systems in the brain. A2AR-based modulation may largely be exerted, once disequilibrium of neurotransmitter systems occurs. Third, extracellular adenosine may act at A2ARs and A1Rs with globally opposite functions, or may act at the A2AR in different brain regions with its differential action to exert modulating effects. The balanced outcome of adenosine actions may be in part controlled by neuroadaptation or maladaptation of neurotransmission, by which it exerts its effect and may in part depend on the preferential sites of pharmacological reagent activity.

ACKNOWLEDGEMENT

This work has been supported by the National Institute of Health (MH083973 and DA19362).

REFERENCES

1. Agnati LF, Fuxe K, Zini I, Lenzi P, Hokfelt T. Aspects on receptor regulation and isoreceptor identification. Med. Biol. 1980;58:182–187. [PubMed]
2. Akhondzadeh S, Safarcherati A, Amini H. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2005;29:253–259. [PubMed]
3. Akhondzadeh S, Shasavand E, Jamilian H, Shabestari O, Kamalipour A. Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions. J. Clin. Pharm. Ther. 2000;25:131–137. [PubMed]
4. Alsene K, Deckert J, Sand P, de Wit H. Association between A2a receptor gene polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology. 2003;28:1694–1702. [PubMed]
5. Alsene KM, Wachtel S, Jurgen D, Wit Hd. Annual meeting for Society for Neuroscience. Orlando, Florida: 2002. Polymorphisms in the adenosine A2A receptor gene are related to caffeine-induced anxiety.
6. Andersson M, Usiello A, Borgkvist A, Pozzi L, Dominguez C, Fienberg AA, Svenningsson P, Fredholm BB, Borrelli E, Greengard P, Fisone G. Cannabinoid action depends on phosphorylation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa at the protein kinase A site in striatal projection neurons. J. Neurosci. 2005;25:8432–8438. [PubMed]
7. Augood SJ, Emson PC. Adenosine A2a receptor mRNA is expressed by enkephalin cells but not by somatostatin cells in rat striatum: a co-expression study. Brain. Res. Mol. Brain Res. 1994;22:204–210. [PubMed]
8. Baddeley AD, Bressi S, Della Sala S, Logie R, Spinnler H. The decline of working memory in Alzheimer's disease. A longitudinal study. Brain. 1991;114(Pt 6):2521–2542. [PubMed]
9. Baldo BA, Koob GF, Markou A. Role of adenosine A2 receptors in brain stimulation reward under baseline conditions and during cocaine withdrawal in rats. J. Neurosci. 1999;19:11017–11026. [PubMed]
10. Bastia E, Xu YH, Scibelli AC, Day YJ, Linden J, Chen JF, Schwarzschild MA. A crucial role for forebrain adenosine A(2A) receptors in amphetamine sensitization. Neuropsychopharmacology. 2005;30:891–900. [PubMed]
11. Belmaker RH, Agam G, Bersudsky Y. Role of GSK3beta in behavioral abnormalities induced by serotonin deficiency. Proc. Natl. Acad. Sci. USA. 2008;105:E23. [PubMed]
12. Bernard V, Bolam JP. Subcellular and subsynaptic distribution of the NR1 subunit of the NMDA receptor in the neostriatum and globus pallidus of the rat co-localization at synapses with the GluR2/3 subunit of the AMPA receptor. Eur. J. Neurosci. 1998;10:3721–3736. [PubMed]
13. Berrendero F, Castane A, Ledent C, Parmentier M, Maldonado R, Valverde O. Increase of morphine withdrawal in mice lacking A2a receptors and no changes in CB1/A2a double knockout mice. Eur. J. Neurosci. 2003;17:315–324. [PubMed]
14. Bibb JA, Snyder GL, Nishi A, Yan Z, Meijer L, Fienberg AA, Tsai LH, Kwon YT, Girault JA, Czernik AJ, Huganir RL, Hemmings HC, Jr., Nairn AC, Greengard P. Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature. 1999;402:669–671. [PubMed]
15. Bilbao A, Cippitelli A, Martin AB, Granado N, Ortiz O, Bezard E, Chen JF, Navarro M, Rodriguez de Fonseca F, Moratalla R. Absence of quasi-morphine withdrawal syndrome in adenosine A2A receptor knockout mice. Psychopharmacology (Berl.) 2006;185:160–168. [PubMed]
16. Brown RM, Short JL. Adenosine A(2A) receptors and their role in drug addiction. J. Pharm. Pharmacol. 2008;60:1409–1430. [PubMed]
17. Brown RM, Short JL, Cowen MS, Ledent C, Lawrence AJ. A differential role for the adenosine A2A receptor in opiate reinforcement vs opiate-seeking behavior. Neuropsychopharmacology. 2009;34:844–856. [PubMed]
18. Canals M, Marcellino D, Fanelli F, Ciruela F, de Benedetti P, Goldberg SR, Neve K, Fuxe K, Agnati LF, Woods AS, Ferre S, Lluis C, Bouvier M, Franco R. Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J. Biol. Chem. 2003;278:46741–46749. [PubMed]
19. Carriba P, Ortiz O, Patkar K, Justinova Z, Stroik J, Themann A, Muller C, Woods AS, Hope BT, Ciruela F, Casado V, Canela EI, Lluis C, Goldberg SR, Moratalla R, Franco R, Ferre S. Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. Neuropsychopharmacology. 2007;32:2249–2259. [PubMed]
20. Chen J-F, Moratalla R, Yu L-Q, Ana B. Mart AB, Xu K, Bastia E, Hackett E, Israel Alberti I, Schwarzschild MA. Inactivation of adenosine A2A receptors selectively attenuates amphetamine-induced behavioral sensitization. Neuropsychopharmacology. 2003;28:1086–1095. [PubMed]
21. Chen JF, Moratalla R, Impagnatiello F, Grandy DK, Cuellar B, Rubinstein M, Beilstein MA, Hackett E, Fink JS, Low MJ, Ongini E, Schwarzschild MA. The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice. Proc. Natl. Acad. Sci. USA. 2001;98:1970–1975. [PubMed]
22. Chen JF, Sonsalla PK, Pedata F, Melani A, Domenici MR, Popoli P, Geiger J, Lopes LV, de Mendonca A. Adenosine A2A receptors and brain injury broad spectrum of neuroprotection, multifaceted actions and "fine tuning" modulation. Prog. Neurobiol. 2007;83:310–331. [PubMed]
23. Ciruela F, Burgueno J, Casado V, Canals M, Marcellino D, Goldberg SR, Bader M, Fuxe K, Agnati LF, Lluis C, Franco R, Ferre S, Woods AS. Combining mass spectrometry and pull-down techniques for the study of receptor heteromerization. Direct epitope-epitope electrostatic interactions between adenosine A2A and dopamine D2 receptors. Anal. Chem. 2004;76:5354–5363. [PubMed]
24. Ciruela F, Casado V, Rodrigues RJ, Lujan R, Burgueno J, Canals M, Borycz J, Rebola N, Goldberg SR, Mallol J, Cortes A, Canela EI, Lopez-Gimenez JF, Milligan G, Lluis C, Cunha RA, Ferre S, Franco R. Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J. Neurosci. 2006;26:2080–2087. [PubMed]
25. Coccurello R, Breysse N, Amalric M. Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats. Neuropsychopharmacology. 2004;29:1451–1461. [PubMed]
26. Comer SD, Carroll ME. Oral caffeine pretreatment produced modest increases in smoked cocaine self-administration in rhesus monkeys. Psychopharmacology (Berl.) 1996;126:281–285. [PubMed]
27. Correa M, Font L. Is there a major role for adenosine A2A receptors in anxiety? Front Biosci. 2008;13:4058–4070. [PubMed]
28. Cryan JF, Slattery DA. Animal models of mood disorders: Recent developments. Curr. Opin. Psychiatry. 2007;20:1–7. [PubMed]
29. Cunha GM, Canas PM, Melo CS, Hockemeyer J, Muller CE, Oliveira CR, Cunha RA. Adenosine A2A receptor blockade prevents memory dysfunction caused by beta-amyloid peptides but not by scopolamine or MK-801. Exp. Neurol. 2008;210:776–781. [PubMed]
30. Cunha GM, Canas PM, Oliveira CR, Cunha RA. Increased density and synapto-protective effect of adenosine A2A receptors upon sub-chronic restraint stress. Neuroscience. 2006;141:1775–1781. [PubMed]
31. Cunha RA. Adenosine as a neuromodulator and as a homeostatic regulator in the nervous system: different roles, different sources and different receptors. Neurochem. Int. 2001;38:107–125. [PubMed]
32. Cunha RA. Neuroprotection by adenosine in the brain: From A1 receptor activation to A2A receptor blockade. Puringergic Signal. 2005;1:111–134. [PMC free article] [PubMed]
33. Cunha RA, Constantino MC, Sebastiao AM, Ribeiro JA. Modification of A1 and A2a adenosine receptor binding in aged striatum, hippocampus and cortex of the rat. Neuroreport. 1995;6:1583–1588. [PubMed]
34. Cunha RA, Ferre S, Vaugeois JM, Chen JF. Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders. Curr. Pharm. Des. 2008;14:1512–1524. [PMC free article] [PubMed]
35. Cunha RA, Johansson B, Constantino MD, Sebastiao AM, Fredholm BB. Evidence for high-affinity binding sites for the adenosine A2A receptor agonist [3H] CGS 21680 in the rat hippocampus and cerebral cortex that are different from striatal A2A receptors. Naunyn Schmiedebergs Arch. Pharmacol. 1996;353:261–271. [PubMed]
36. Cunha RA, Ribeiro JA. Purinergic modulation of [(3)H]GABA release from rat hippocampal nerve terminals. Neuropharmacology. 2000;39:1156–1167. [PubMed]
37. Dall'igna OP, Fett P, Gomes MW, Souza DO, Cunha RA, Lara DR. Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice. Exp. Neurol. 2007;203:241–245. [PubMed]
38. Dassesse D, Massie A, Ferrari R, Ledent C, Parmentier M, Arckens L, Zoli M, Schiffmann SN. Functional striatal hypodopaminergic activity in mice lacking adenosine A(2A) receptors. J. Neurochem. 2001;78:183–198. [PubMed]
39. De Freitas B, Schwartz G. Effects of caffeine in chronic psychiatric patients. Am. J. Psychiatry. 1979;136:1337–1338. [PubMed]
40. de Mendonca A, Sebastiao AM, Ribeiro JA. Inhibition of NMDA receptor-mediated currents in isolated rat hippocampal neurones by adenosine A1 receptor activation. Neuroreport. 1995;6:1097–1100. [PubMed]
41. Deckert J, Gleiter CH. Adenosinergic psychopharmaceuticals? Trends Pharmacol. Sci. 1989;10:99–100. [PubMed]
42. Deckert J, Nothen MM, Bryant SP, Schuffenhauer S, Schofield PR, Spurr NK, Propping P. Mapping of the human adenosine A2a receptor gene: relationship to potential schizophrenia loci on chromosome 22q and exclusion from the CATCH 22 region. Hum. Genet. 1997;99:326–328. [PubMed]
43. Di Iorio P, Battaglia G, Ciccarelli R, Ballerini P, Giuliani P, Poli A, Nicoletti F, Caciagli F. Interaction between A1 adenosine and class II metabotropic glutamate receptors in the regulation of purine and glutamate release from rat hippocampal slices. J. Neurochem. 1996;67:302–309. [PubMed]
44. Diaz-Cabiale Z, Vivo M, Del Arco A, O'Connor WT, Harte MK, Muller CE, Martinez E, Popoli P, Fuxe K, Ferre S. Metabotropic glutamate mGlu5 receptor-mediated modulation of the ventral striopallidal GABA pathway in rats Interactions with adenosine A(2A) and dopamine D(2) receptors. Neurosci. Lett. 2002;324:154–158. [PubMed]
45. Diogenes MJ, Fernandes CC, Sebastiao AM, Ribeiro JA. Activation of adenosine A2A receptor facilitates brain-derived neurotrophic factor modulation of synaptic transmission in hippocampal slices. J. Neurosci. 2004;24:2905–2913. [PubMed]
46. Dixon AK, Widdowson L, Richardson PJ. Desensitisation of the adenosine A1 receptor by the A2A receptor in the rat striatum. J. Neurochem. 1997;69:315–321. [PubMed]
47. Dunwiddie TV, Masino SA. The role and regulation of adenosine in the central nervous system. Annu. Rev. Neurosci. 2001;24:31–55. [PubMed]
48. El Yacoubi M, Costentin J, Vaugeois JM. Adenosine A2A receptors and depression. Neurology. 2003;61:S82–87. [PubMed]
49. El Yacoubi M, Ledent C, Parmentier M, Bertorelli R, Ongini E, Costentin J, Vaugeois JM. Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice. Br. J. Pharmacol. 2001;134:68–77. [PubMed]
50. El Yacoubi M, Ledent C, Parmentier M, Costentin J, Vaugeois JM. The anxiogenic-like effect of caffeine in two experimental procedures measuring anxiety in the mouse is not shared by selective A(2A) adenosine receptor antagonists. Psychopharmacology (Berl.) 2000;148:153–163. [PubMed]
51. El Yacoubi M, Vaugeois JM. Genetic rodent models of depression. Curr. Opin. Pharmacol. 2007;7:3–7. [PubMed]
52. Fenu S, Pinna A, Ongini E, Morelli M. Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. Eur. J. Pharmacol. 1997;321:143–147. [PubMed]
53. Ferre S. An update on the mechanisms of the psychostimulant effects of caffeine. J. Neurochem. 2008;105:1067–1079. [PubMed]
54. Ferre S, Agnati LF, Ciruela F, Lluis C, Woods AS, Fuxe K, Franco R. Neurotransmitter receptor heteromers and their integrative role in 'local modules': the striatal spine module. Brain Res. Rev. 2007;55:55–67. [PMC free article] [PubMed]
55. Ferre S, Ciruela F, Canals M, Marcellino D, Burgueno J, Casado V, Hillion J, Torvinen M, Fanelli F, Benedetti Pd P, Goldberg SR, Bouvier M, Fuxe K, Agnati LF, Lluis C, Franco R, Woods A. Adenosine A2A-dopamine D2 receptor-receptor heteromers. Targets for neuro-psychiatric disorders. Parkinsonism Relat. Disord. 2004;10:265–271. [PubMed]
56. Ferre S, Fredholm BB, Morelli M, Popoli P, Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integra-tive mechanism in the basal ganglia. Trends Neurosci. 1997;20:482–487. [PubMed]
57. Ferre S, Karcz-Kubicha M, Hope BT, Popoli P, Burgueno J, Gutierrez MA, Casado V, Fuxe K, Goldberg SR, Lluis C, Franco R, Ciruela F. Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: implications for striatal neuronal function. Proc. Natl. Acad. Sci. USA. 2002;99:11940–11945. [PubMed]
58. Ferre S, Popoli P, Rimondini R, Reggio R, Kehr J, Fuxe K. Adenosine A2A and group I metabotropic glutamate receptors synergistically modulate the binding characteristics of dopamine D2 receptors in the rat striatum. Neuropharmacology. 1999;38:129–140. [PubMed]
59. Ferre S, von Euler G, Johansson B, Fredholm BB, Fuxe K. Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proc. Natl. Acad. Sci. USA. 1991;88:7238–7241. [PubMed]
60. Filip M, Frankowska M, Zaniewska M, Przegalinski E, Mul-ler CE, Agnati L, Franco R, Roberts DC, Fuxe K. Involvement of adenosine A2A and dopamine receptors in the locomotor and sensitizing effects of cocaine. Brain Res. 2006;1077:67–80. [PubMed]
61. Fink JS, Weaver DR, Rivkees SA, Peterfreund RA, Pollack AE, Adler EM, Reppert SM. Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Brain Res. Mol. Brain Res. 1992;14:186–195. [PubMed]
62. Fredholm BB. Adenosine receptors as targets for drug development. Drug News Perspect. 2003;16:283–289. [PubMed]
63. Fredholm BB, Chen JF, Cunha RA, Svenningsson P, Vaugeois JM. Adenosine and brain function. Int. Rev. Neurobiol. 2005;63:191–270. [PubMed]
64. Fredholm BB, Chen JF, Masino SA, Vaugeois JM. Actions of adenosine at its receptors in the CNS: insights from knockouts and drugs. Annu. Rev. Pharmacol. Toxicol. 2005;45:385–412. [PubMed]
65. Fredholm BB, Cunha RA, Svenningsson P. Pharmacology of Adenosine A(2A) Receptors and Therapeutic Applications. Curr. Top. Med. Chem. 2003;3:413–426. [PubMed]
66. Fredholm BB, Dunwiddie TV. How does adenosine inhibit transmitter release? Trends Pharmacol. Sci. 1988;9:130–134. [PubMed]
67. Furuichi E, Koehl P. Influence of protein structure databases on the predictive power of statistical pair potentials. Proteins Struct. Funct. Genetics. 1998;31:139–149. [PubMed]
68. Fuxe K, Agnati LF, Jacobsen K, Hillion J, Canals M, Tor-vinen M, Tinner-Staines B, Staines W, Rosin D, Terasmaa A, Popoli P, Leo G, Vergoni V, Lluis C, Ciruela F, Franco R, Ferre S. Receptor heteromerization in adenosine A2A receptor signaling relevance for striatal function and Parkinson's disease. Neurology. 2003;61:S19–23. [PubMed]
69. Fuxe K, Ferre S, Canals M, Torvinen M, Terasmaa A, Marcellino D, Goldberg SR, Staines W, Jacobsen KX, Lluis C, Woods AS, Agnati LF, Franco R. Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function. J. Mol. Neurosci. 2005;26:209–220. [PubMed]
70. Fuxe K, Kohler C, Agnati LF, Andersson K, Ogren SO, Eneroth P, Perez de la Mora M, Karobath M, Krogsgaard-Larsen P. GABA and benzodiazepine receptors Studies on their localization in the hippocampus and their interaction with central dopamine neurons in the rat brain. Adv. Biochem. Psychopharmacol. 1981;26:61–76. [PubMed]
71. Fuxe K, Marcellino D, Guidolin D, Woods AS, Agnati LF. Heterodimers and receptor mosaics of different types of G-protein-coupled receptors. Physiology (Bethesda) 2008;23:322–332. [PubMed]
72. Gao WJ, Krimer LS, Goldman-Rakic PS. Presynaptic regulation of recurrent excitation by D1 receptors in prefrontal circuits. Proc. Natl. Acad. Sci. USA. 2001;98:295–300. [PubMed]
73. Gasior M, Jaszyna M, Peters J, Goldberg SR. Changes in the ambulatory activity and discriminative stimulus effects of psychostimulant drugs in rats chronically exposed to caffeine: effect of caffeine dose. J. Pharmacol. Exp. Ther. 2000;295:1101–1111. [PubMed]
74. Gauvin DV, Criado JR, Moore KR, Holloway FA. Potentiation of cocaine's discriminative effects by caffeine: a time-effect analysis. Pharmacol. Biochem. Behav. 1990;36:195–197. [PubMed]
75. Geiger JD, Glavin GB. Adenosine receptor activation in brain reduces stress-induced ulcer formation. Eur. J. Pharmacol. 1985;115:185–190. [PubMed]
76. Gerevich Z, Wirkner K, Illes P. Adenosine A2A receptors inhibit the N-methyl-D-aspartate component of excitatory synaptic currents in rat striatal neurons. Eur. J. Pharmacol. 2002;451:161–164. [PubMed]
77. Ghisolfi ES, Prokopiuk AS, Becker J, Ehlers JA, Belmonte-de-Abreu P, Souza DO, Lara DR. The adenosine antagonist theophylline impairs p50 auditory sensory gating in normal subjects. Neuropsychopharmacology. 2002;27:629–637. [PubMed]
78. Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br. J. Pharmacol. 2007;151:737–748. [PubMed]
79. Gimenez-Llort L, Fernandez-Teruel A, Escorihuela RM, Fredholm BB, Tobena A, Pekny M, Johansson B. Mice lacking the adenosine A1 receptor are anxious and aggressive, but are normal learners with reduced muscle strength and survival rate. Eur. J. Neurosci. 2002;16:547–550. [PubMed]
80. Goldman-Rakic PS. The physiological approach: functional architecture of working memory and disordered cognition in schizophrenia. Biol. Psychiatry. 1999;46:650–661. [PubMed]
81. Goldman-Rakic PS, Castner SA, Svensson TH, Siever LJ, Williams GV. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl.) 2004;174:3–16. [PubMed]
82. Golembiowska K, Zylewska A. Agonists of A1 and A2A adenosine receptors attenuate methamphetamine-induced overflow of dopamine in rat striatum. Brain Res. 1998;806:202–209. [PubMed]
83. Greden JF. Anxiety or caffeinism: a diagnostic dilemma. Am. J. Psychiatry. 1974;131:1089–1092. [PubMed]
84. Green PJ, Suls J. The effects of caffeine on ambulatory blood pressure, heart rate, and mood in coffee drinkers. J. Behav. Med. 1996;19:111–128. [PubMed]
85. Greengard P, Nairn AC, Girault JA, Ouimet CC, Snyder GL, Fisone G, Allen PB, Fienberg A, Nishi A. The DARPP-32/protein phosphatase-1 cascade: a model for signal integration. Brain Res. Brain Res. Rev. 1998;26:274–284. [PubMed]
86. Grondin R, Bedard PJ, Hadj Tahar A, Gregoire L, Mori A, Kase H. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology. 1999;52:1673–1677. [PubMed]
87. Haskell CF, Kennedy DO, Wesnes KA, Scholey AB. Cognitive and mood improvements of caffeine in habitual consumers and habitual non-consumers of caffeine. Psychopharmacology (Berl.) 2005;179:813–825. [PubMed]
88. Hauber W, Neuscheler P, Nagel J, Muller CE. Catalepsy induced by a blockade of dopamine D1 or D2 receptors was reversed by a concomitant blockade of adenosine A(2A) receptors in the caudate-putamen of rats. Eur. J. Neurosci. 2001;14:1287–1293. [PubMed]
89. Heffner TG, Wiley JN, Williams AE, Bruns RF, Coughenour LL, Downs DA. Comparison of the behavioral effects of adenosine agonists and dopamine antagonists in mice. Psychopharmacology. 1989;98:31–37. [PubMed]
90. Hernandez-Lopez S, Tkatch T, Perez-Garci E, Galarraga E, Bargas J, Hamm H, Surmeier DJ. D2 dopamine receptors in striatal medium spiny neurons reduce L-type Ca2+ currents and excitability via a novel PLC[beta]1-IP3-calcineurin-signaling cascade. J. Neurosci. 2000;20:8987–8995. [PubMed]
91. Hillion J, Canals M, Torvinen M, Casado V, Scott R, Terasmaa A, Hansson A, Watson S, Olah ME, Mallol J, Canela EI, Zoli M, Agnati LF, Ibanez CF, Lluis C, Franco R, Ferre S, Fuxe K. Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors. J. Biol. Chem. 2002;277:18091–18097. [PubMed]
92. Hong CJ, Liu HC, Liu TY, Liao DL, Tsai SJ. Association studies of the adenosine A2a receptor (1976T > C) genetic polymorphism in Parkinson's disease and schizophrenia. J. Neural. Transm. 2005;112:1503–1510. [PubMed]
93. Hunter AM, Balleine BW, Minor TR. Helplessness and escape performance glutamate-adenosine interactions in the frontal cortex. Behav. Neurosci. 2003;117:123–135. [PubMed]
94. James S, Richardson PJ. The subcellular distribution of [3H]-CGS 21680 binding sites in the rat striatum: copurification with cholinergic nerve terminals. Neurochem. Int. 1993;23:115–122. [PubMed]
95. Jeanneteau F, Chao MV. Promoting neurotrophic effects by GPCR ligands. Novartis Found Symp. 2006;276:181–189. discussion 189-192, 233-187, 275-181. [PubMed]
96. Jegou S, El Yacoubi M, Mounien L, Ledent C, Parmentier M, Costentin J, Vaugeois JM, Vaudry H. Adenosine A2A receptor gene disruption provokes marked changes in melanocortin content and pro-opiomelanocortin gene expression. J. Neuroendocrinol. 2003;15:1171–1177. [PubMed]
97. Justinova Z, Ferre S, Segal PN, Antoniou K, Solinas M, Pappas LA, Highkin JL, Hockemeyer J, Munzar P, Goldberg SR. Involvement of adenosine A1 and A2A receptors in the adenosinergic modulation of the discriminative-stimulus effects of cocaine and methamphetamine in rats. J. Pharmacol. Exp. Ther. 2003;307:977–986. [PubMed]
98. Kachroo A, Orlando LR, Grandy DK, Chen JF, Young AB, Schwarzschild MA. Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice. J. Neurosci. 2005;25:10414–10419. [PubMed]
99. Kalueff AV. Neurobiology of memory and anxiety: from genes to behavior. Neural. Plast. 2007;2007:78171. [PMC free article] [PubMed]
100. Kalueff AV, Murphy DL. The importance of cognitive phenotypes in experimental modeling of animal anxiety and depression. Neural. Plast. 2007;2007:52087. [PMC free article] [PubMed]
101. Kalueff AV, Wheaton M, Murphy DL. What's wrong with my mouse model? Advances and strategies in animal modeling of anxiety and depression. Behav. Brain Res. 2007;179:1–18. [PubMed]
102. Kanda T, Shiozaki S, Shimada J, Suzuki F, Nakamura J. KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity. Eur. J. Pharmacol. 1994;256:263–268. [PubMed]
103. Kanda T, Tashiro T, Kuwana Y, Jenner P. Adenosine A2A receptors modify motor function in MPTP-treated common marmosets. Neuroreport. 1998;9:2857–2860. [PubMed]
104. Kaster MP, Budni J, Santos AR, Rodrigues AL. Pharmacological evidence for the involvement of the opioid system in the antidepressant-like effect of adenosine in the mouse forced swimming test. Eur. J. Pharmacol. 2007;576:91–98. [PubMed]
105. Kaster MP, Rosa AO, Rosso MM, Goulart EC, Santos AR, Rodrigues AL. Adenosine administration produces an antidepressant-like effect in mice: evidence for the involvement of A1 and A2A receptors. Neurosci. Lett. 2004;355:21–24. [PubMed]
106. Kaster MP, Rosa AO, Santos AR, Rodrigues AL. Involvement of nitric oxide-cGMP pathway in the antidepressant-like effects of adenosine in the forced swimming test. Int. J. Neuropsychopharmacol. 2005;8:601–606. [PubMed]
107. Kensinger EA, Shearer DK, Locascio JJ, Growdon JH, Corkin S. Working memory in mild Alzheimer's disease and early Parkinson's disease. Neuropsychology. 2003;17:230–239. [PubMed]
108. Kirk IP, Richardson PJ. Adenosine A2a receptor-mediated modulation of striatal [3H]GABA and [3H]acetylcholine release. J. Neurochem. 1994;62:960–966. [PubMed]
109. Kirk IP, Richardson PJ. Inhibition of striatal GABA release by the adenosine A2a receptor is not mediated by increases in cyclic AMP. J. Neurochem. 1995;64:2801–2809. [PubMed]
110. Kirkpatrick KA, Richardson PJ. Adenosine receptor-mediated modulation of acetylcholine release from rat striatal synaptosomes. Br. J. Pharmacol. 1993;110:949–954. [PubMed]
111. Knapp CM, Foye MM, Cottam N, Ciraulo DA, Kornetsky C. Adenosine agonists CGS 21680 and NECA inhibit the initiation of cocaine self-administration. Pharmacol. Biochem. Behav. 2001;68:797–803. [PubMed]
112. Kulkarni SK, Mehta AK. Purine nucleoside--mediated immobility in mice: reversal by antidepressants. Psychopharmacology (Berl.) 1985;85:460–463. [PubMed]
113. Kulkarni SK, Singh K, Bishnoi M. Involvement of adenosinergic receptors in anxiety related behaviours. Indian J. Exp. Biol. 2007;45:439–443. [PubMed]
114. Kull B, Ferre S, Arslan G, Svenningsson P, Fuxe K, Owman C, Fredholm BB. Reciprocal interactions between adenosine A2A and dopamine D2 receptors in Chinese hamster ovary cells co-transfected with the two receptors. Biochem. Pharmacol. 1999;58:1035–1045. [PubMed]
115. Lader M, Bruce M. States of anxiety and their induction by drugs. Br. J. Clin. Pharmacol. 1986;22:251–261. [PubMed]
116. Lara DR, Brunstein MG, Ghisolfi ES, Lobato MI, Belmonte-de-Abreu P, Souza DO. Allopurinol augmentation for poorly responsive schizophrenia. Int. Clin. Psychopharmacol. 2001;16:235–237. [PubMed]
117. Lara DR, Dall'Igna OP, Ghisolfi ES, Brunstein MG. Involvement of adenosine in the neurobiology of schizophrenia and its therapeutic implications. Prog. Neuropsychopharmacol. Biol. Psychiatr. 2006;30:617–629. [PubMed]
118. Lara DR, Souza DO. Adenosine and antidepressant effects of sleep deprivation. Am. J. Psychiatr. 2000;157:1707–1708. [PubMed]
119. Lara DR, Vianna MR, de Paris F, Quevedo J, Oses JP, Battastini AM, Sarkis JJ, Souza DO. Chronic treatment with clozapine, but not haloperidol, increases striatal ecto-5'-nucleotidase activity in rats. Neuropsychobiology. 2001;44:99–102. [PubMed]
120. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J. Cereb. Blood Flow Metab. 2000;20:423–451. [PubMed]
121. Latini S, Pazzagli M, Pepeu G, Pedata F. A2 adenosine receptors: their presence and neuromodulatory role in the central nervous system. Gen. Pharmacol. 1996;27:925–933. [PubMed]
122. Ledent C, Vaugeois JM, Schiffmann SN, Pedrazzini T, El Yacoubi M, Vanderhaeghen JJ, Costentin J, Heath JK, Vassart G, Parmentier M. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature. 1997;388:674–678. [PubMed]
123. Lee FS, Chao MV. Activation of Trk neurotrophin receptors in the absence of neurotrophins. Proc. Natl. Acad. Sci. USA. 2001;98:3555–3560. [PubMed]
124. Lieberman HR, Tharion WJ, Shukitt-Hale B, Speckman KL, Tulley R. Effects of caffeine, sleep loss, and stress on cognitive performance and mood during U.S. Navy SEAL training. Sea-Air-Land. Psychopharmacology (Berl.) 2002;164:250–261. [PubMed]
125. Lieberman HR, Wurtman RJ, Emde GG, Coviella IL. The effects of caffeine and aspirin on mood and performance. J. Clin. Psychopharmacol. 1987;7:315–320. [PubMed]
126. Lim HK, Juh R, Pae CU, Lee BT, Yoo SS, Ryu SH, Kwak KR, Lee C, Lee CU. Altered verbal working memory process in patients with Alzheimer's disease: an fMRI investigation. Neuropsychobiology. 2008;57:181–187. [PubMed]
127. Lindskog M, Svenningsson P, Fredholm BB, Greengard P, Fisone G. Activation of dopamine D2 receptors decreases DARPP-32 phosphorylation in striatonigral and striatopallidal projection neurons via different mechanisms. Neuroscience. 1999;88:1005–1008. [PubMed]
128. Lindskog M, Svenningsson P, Pozzi L, Kim Y, Fienberg AA, Bibb JA, Fredholm BB, Nairn AC, Greengard P, Fisone G. Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine. Nature. 2002;418:774–778. [PubMed]
129. Loke WH. Effects of caffeine on mood and memory. Physiol. Behav. 1988;44:367–372. [PubMed]
130. Lopes LV, Cunha RA, Kull B, Fredholm BB, Ribeiro JA. Adenosine A(2A) receptor facilitation of hippocampal synaptic transmission is dependent on tonic A(1) receptor inhibition. Neuroscience. 2002;112:319–329. [PubMed]
131. Lopes LV, Cunha RA, Ribeiro JA. Cross talk between A(1) and A(2A) adenosine receptors in the hippocampus and cortex of young adult and old rats. J. Neurophysiol. 1999;82:3196–3203. [PubMed]
132. Lucas PB, Pickar D, Kelsoe J, Rapaport M, Pato C, Hommer D. Effects of the acute administration of caffeine in patients with schizophrenia. Biol. Psychiatry. 1990;28:35–40. [PubMed]
133. Maletic V, Robinson M, Oakes T, Iyengar S, Ball SG, Russell J. Neurobiology of depression: an integrated view of key findings. Int. J. Clin. Pract. 2007;61:2030–2040. [PMC free article] [PubMed]
134. Marchi M, Raiteri L, Risso F, Vallarino A, Bonfanti A, Monopoli A, Ongini E, Raiteri M. Effects of adenosine A1 and A2A receptor activation on the evoked release of glutamate from rat cerebrocortical synaptosomes. Br. J. Pharmacol. 2002;136:434–440. [PubMed]
135. Martini C, Tuscano D, Trincavelli ML, Cerrai E, Bianchi M, Ciapparelli A, Alessio L, Novelli L, Catena M, Lucacchini A, Cassano GB, Dell'Osso L. Upregulation of A2A adenosine receptors in platelets from patients affected by bipolar disorders under treatment with typical antipsychotics. J. Psychiatr. Res. 2006;40:81–88. [PubMed]
136. Matsushima K, Hogan MJ, Hakim AM. Cortical spreading depression protects against subsequent focal cerebral ischemia in rats. J. Cereb. Blood Flow Metab. 1996;16:221–226. [PubMed]
137. Matsushima K, Schmidt-Kastner R, Hogan MJ, Hakim AM. Cortical spreading depression activates trophic factor expression in neurons and astrocytes and protects against subsequent focal brain ischemia. Brain Res. 1998;807:47–60. [PubMed]
138. Mayo KM, Falkowski W, Jones CA. Caffeine: use and effects in long-stay psychiatric patients. Br. J. Psychiatry. 1993;162:543–545. [PubMed]
139. Melani A, Corsi C, Gimenez-Llort L, Martinez E, Ogren SO, Pedata F, Ferre S. Effect of N-methyl-D-aspartate on motor activity and in vivo adenosine striatal outflow in the rat. Eur. J. Pharmacol. 1999;385:15–19. [PubMed]
140. Mikkelsen EJ. Caffeine and schizophrenia. J. Clin. Psychiatry. 1978;39:732–736. [PubMed]
141. Minor TR, Huang Q, Foley EA. Cytokine-purine interactions in behavioral depression in rats. Integr. Physiol. Behav. Sci. 2003;38:189–202. [PubMed]
142. Minor TR, Winslow JL, Chang WC. Stress and adenosine: II. Adenosine analogs mimic the effect of inescapable shock on shuttle-escape performance in rats. Behav. Neurosci. 1994;108:265–276. [PubMed]
143. Misra AL, Vadlamani NL, Pontani RB. Effect of caffeine on cocaine locomotor stimulant activity in rats. Pharmacol. Biochem. Behav. 1986;24:761–764. [PubMed]
144. Morelli M. Adenosine A2A antagonists: potential preventive and palliative treatment for Parkinson's disease. Exp. Neurol. 2003;184:20–23. [PubMed]
145. Morelli M, Fenu S, Pinna A, Di Chiara G. Adenosine A2 receptors interact negatively with dopamine D1 and D2 receptors in unilaterally 6-hydroxydopamine-lesioned rats. Eur. J. Pharmacol. 1994;251:21–25. [PubMed]
146. Morelli M, Pinna A. Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson's disease. Neurol. Sci. 2001;22:71–72. [PubMed]
147. Munzar P, Justinova Z, Kutkat SW, Ferre S, Goldberg SR. Adenosinergic modulation of the discriminative-stimulus effects of methamphetamine in rats. Psychopharmacology (Berl.) 2002;161:348–355. [PubMed]
148. Nagel J, Schladebach H, Koch M, Schwienbacher I, Muller CE, Hauber W. Effects of an adenosine A2A receptor blockade in the nucleus accumbens on locomotion, feeding, and prepulse inhibition in rats. Synapse. 2003;49:279–286. [PubMed]
149. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron. 2002;34:13–25. [PubMed]
150. Nestler EJ, Gould E, Manji H, Buncan M, Duman RS, Greshenfeld HK, Hen R, Koester S, Lederhendler I, Meaney M, Robbins T, Winsky L, Zalcman S. Preclinical models: status of basic research in depression. Biol. Psychiatry. 2002;52:503–528. [PubMed]
151. Nickell PV, Uhde TW. Dose-response effects of intravenous caffeine in normal volunteers. Anxiety. 1994;1:161–168. [PubMed]
152. Nishi A, Bibb JA, Snyder GL, Higashi H, Nairn AC, Greengard P. Amplification of dopaminergic signaling by a positive feedback loop. Proc. Natl. Acad. Sci. USA. 2000;97:12840–12845. [PubMed]
153. Nishi A, Liu F, Matsuyama S, Hamada M, Higashi H, Nairn AC, Greengard P. Metabotropic mGlu5 receptors regulate adenosine A2A receptor signaling. Proc. Natl. Acad. Sci. USA. 2003;100:1322–1327. [PubMed]
154. Nishizaki T, Nagai K, Nomura T, Tada H, Kanno T, Tozaki H, Li XX, Kondoh T, Kodama N, Takahashi E, Sakai N, Tanaka K, Saito N. A new neuromodulatory pathway with a glial contribution mediated via A(2a) adenosine receptors. Glia. 2002;39:133–147. [PubMed]
155. O'Kane EM, Stone TW. Interaction between adenosine A1 and A2 receptor-mediated responses in the rat hippocampus in vitro. Eur. J. Pharmacol. 1998;362:17–25. [PubMed]
156. Okada M, Nutt DJ, Murakami T, Zhu G, Kamata A, Kawata Y, Kaneko S. Adenosine receptor subtypes modulate two major functional pathways for hippocampal serotonin release. J. Neurosci. 2001;21:628–640. [PubMed]
157. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry. 1995;52:998–1007. [PubMed]
158. Pereira GS, Rossato JI, Sarkis JJ, Cammarota M, Bonan CD, Izquierdo I. Activation of adenosine receptors in the posterior cingulate cortex impairs memory retrieval in the rat. Neurobiol. Learn Mem. 2005;83:217–223. [PubMed]
159. Pinna A, Wardas J, Cozzolino A, Morelli M. Involvement of adenosine A2A receptors in the induction of c-fos expression by clozapine and haloperidol. Neuropsychopharmacology. 1999;20:44–51. [PubMed]
160. Poleszak E, Malec D. Cocaine-induced hyperactivity is more influenced by adenosine receptor agonists than amphetamine-induced hyperactivity. Pol. J. Pharmacol. 2002;54:359–366. [PubMed]
161. Pollack AE, Fink JS. Adenosine antagonists potentiate D2 dopamine-dependent activation of Fos in the striatopallidal pathway. Neuroscience. 1995;68:721–728. [PubMed]
162. Pollack AE, Fink JS. Synergistic interaction between an adenosine antagonist and a D1 dopamine agonist on rotational behavior and striatal c-Fos induction in 6-hydroxydopamine-lesioned rats. Brain Res. 1996;743:124–130. [PubMed]
163. Pollack AE, Harrison MB, Wooten GF, Fink JS. Differential localization of A2a adenosine receptor mRNA with D1 and D2 dopamine receptor mRNA in striatal output pathways following a selective lesion of striatonigral neurons. Brain Res. 1993;631:161–166. [PubMed]
164. Popoli P, Betto P, Reggio R, Ricciarello G. Adenosine A2A receptor stimulation enhances striatal extracellular glutamate levels in rats. Eur. J. Pharmacol. 1995;287:215–217. [PubMed]
165. Popoli P, Pezzola A, de Carolis AS. Modulation of striatal adenosine A1 and A2 receptors induces rotational behaviour in response to dopaminergic stimulation in intact rats. Eur. J. Pharmacol. 1994;257:21–25. [PubMed]
166. Popoli P, Reggio R, Pezzola A. Adenosine A1 and A2 receptor agonists significantly prevent the electroencephalographic effects induced by MK-801 in rats. Eur. J. Pharmacol. 1997;333:143–146. [PubMed]
167. Potter D, Summerfelt A, Gold J, Buchanan RW. Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia. Schizophr. Bull. 2006;32:692–700. [PMC free article] [PubMed]
168. Prediger RD, Da Cunha C, Takahashi RN. Antagonistic interaction between adenosine A2A and dopamine D2 receptors modulates the social recognition memory in reserpine-treated rats. Behav. Pharmacol. 2005;16:209–218. [PubMed]
169. Prediger RD, Fernandes D, Takahashi RN. Blockade of adenosine A2A receptors reverses short-term social memory impairments in spontaneously hypertensive rats. Behav. Brain Res. 2005;159:197–205. [PubMed]
170. Queiroz G, Talaia C, Goncalves J. Adenosine A2A receptor-mediated facilitation of noradrenaline release involves protein kinase C activation and attenuation of presynaptic inhibitory receptor-mediated effects in the rat vas deferens. J. Neurochem. 2003;85:740–748. [PubMed]
171. Rebola N, Canas PM, Oliveira CR, Cunha RA. Different synaptic and subsynaptic localization of adenosine A2A receptors in the hippocampus and striatum of the rat. Neuroscience. 2005;132:893–903. [PubMed]
172. Rebola N, Lujan R, Cunha RA, Mulle C. Adenosine A2A receptors are essential for long-term potentiation of NMDA-EPSCs at hippocampal mossy fiber synapses. Neuron. 2008;57:121–134. [PubMed]
173. Rebola N, Rodrigues RJ, Lopes LV, Richardson PJ, Oliveira CR, Cunha RA. Adenosine A1 and A2A receptors are co-expressed in pyramidal neurons and co-localized in glutamatergic nerve terminals of the rat hippocampus. Neuroscience. 2005;133:79–83. [PubMed]
174. Ribeiro JA. Adenosine A2A receptor interactions with receptors for other neurotransmitters and neuromodulators. Eur. J. Pharmacol. 1999;375:101–113. [PubMed]
175. Ribeiro JA, Sebastiao AM, de Mendonca A. Adenosine receptors in the nervous system: pathophysiological implications. Prog. Neurobiol. 2002;68:377–392. [PubMed]
176. Rimondini R, Ferre S, Ogren SO, Fuxe K. Adenosine A2A agonists: a potential new type of atypical antipsychotic. Neuropsychopharmacology. 1997;17:82–91. [PubMed]
177. Rodrigues RJ, Alfaro TM, Rebola N, Oliveira CR, Cunha RA. Co-localization and functional interaction between adenosine A(2A) and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum. J. Neurochem. 2005;92:433–441. [PubMed]
178. Sahraei H, Motamedi F, Khoshbaten A, Zarrindast MR. Adenosine A(2) receptors inhibit morphine self-administration in rats. Eur. J. Pharmacol. 1999;383:107–113. [PubMed]
179. Scaccianoce S, Navarra D, Di Sciullo A, Angelucci L, Endroczi E. Adenosine and pituitary-adrenocortical axis activity in the rat. Neuroendocrinology. 1989;50:464–468. [PubMed]
180. Schiffmann SN, Dassesse D, d'Alcantara P, Ledent C, Swil-lens S, Zoli M. A2A receptor and striatal cellular functions: regulation of gene expression, currents, and synaptic transmission. Neurology. 2003;61:S24–29. [PubMed]
181. Schiffmann SN, Fisone G, Moresco R, Cunha RA, Ferre S. Adenosine A2A receptors and basal ganglia physiology. Prog. Neurobiol. 2007;83:277–292. [PMC free article] [PubMed]
182. Schiffmann SN, Jacobs O, Vanderhaeghen JJ. Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J. Neurochem. 1991;57:1062–1067. [PubMed]
183. Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M. Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci. 2006;29:647–654. [PubMed]
184. Sebastiao AM, Ribeiro JA. Adenosine A2 receptor-mediated excitatory actions on the nervous system. Prog. Neurobiol. 1996;48:167–189. [PubMed]
185. Sebastiao AM, Ribeiro JA. Adenosine A2 receptor-mediated excitatory actions on the nervous system. Prog. Neurobiol. 1996;48:167–189. [PubMed]
186. Sebastiao AM, Ribeiro JA. Fine-tuning neuromodulation by adenosine. Trends Pharmacol. Sci. 2000;21:341–346. [PubMed]
187. Seeman P, Schwarz J, Chen JF, Szechtman H, Perreault M, McKnight GS, Roder JC, Quirion R, Boksa P, Srivastava LK, Yanai K, Weinshenker D, Sumiyoshi T. Psychosis pathways converge via D2high dopamine receptors. Synapse. 2006;60:319–346. [PubMed]
188. Shen HY, Coelho JE, Ohtsuka N, Canas PM, Day YJ, Huang QY, Rebola N, Yu L, Boison D, Cunha RA, Linden J, Tsien JZ, Chen JF. A critical role of the adenosine A2A receptor in extrastriatal neurons in modulating psychomotor activity as revealed by opposite phenotypes of striatum and forebrain A2A receptor knock-outs. J. Neurosci. 2008;28:2970–2975. [PubMed]
189. Shimazoe T, Yoshimatsu A, Kawashimo A, Watanabe S. Roles of adenosine A(1) and A(2A) receptors in the expression and development of methamphetamine-induced sensitization. Eur. J. Pharmacol. 2000;388:249–254. [PubMed]
190. Shiozaki S, Ichikawa S, Nakamura J, Kitamura S, Yamada K, Kuwana Y. Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology (Berl.) 1999;147:90–95. [PubMed]
191. Short JL, Ledent C, Borrelli E, Drago J, Lawrence AJ. Genetic interdependence of adenosine and dopamine receptors: evidence from receptor knockout mice. Neuroscience. 2006;139:661–670. [PubMed]
192. Sicard BA, Perault MC, Enslen M, Chauffard F, Vandel B, Tachon P. The effects of 600 mg of slow release caffeine on mood and alertness. Aviat. Space. Environ. Med. 1996;67:859–862. [PubMed]
193. Sills TL, Azampanah A, Fletcher PJ. The adenosine A1 receptor agonist N6-cyclopentyladenosine blocks the disruptive effect of phencyclidine on prepulse inhibition of the acoustic startle response in the rat. Eur. J. Pharmacol. 1999;369:325–329. [PubMed]
194. Snyder SH. Adenosine as a neuromodulator. Annu. Rev. Neurosci. 1985;8:103–124. [PubMed]
195. Soares JC, Gershon S. Therapeutic targets in late-life psychoses: review of concepts and critical issues. Schizophr. Res. 1997;27:227–239. [PubMed]
196. Soria G, Castane A, Ledent C, Parmentier M, Maldonado R, Valverde O. The lack of A2A adenosine receptors diminishes the reinforcing efficacy of cocaine. Neuropsychopharmacology. 2006;31:978–987. [PubMed]
197. Southwick SM, Vythilingam M, Charney DS. The psychobiology of depression and resilience to stress: implications for prevention and treatment. Annu. Rev. Clin. Psychol. 2005;1:255–291. [PubMed]
198. Stern KN, Chait LD, Johanson CE. Reinforcing and subjective effects of caffeine in normal human volunteers. Psychopharmacology (Berl.) 1989;98:81–88. [PubMed]
199. Stromberg I, Popoli P, Muller CE, Ferre S, Fuxe K. Electrophysiological and behavioural evidence for an antagonistic modulatory role of adenosine A2A receptors in dopamine D2 receptor regulation in the rat dopamine-denervated striatum. Eur. J. Neurosci. 2000;12:4033–4037. [PubMed]
200. Surmeier DJ. Calcium, ageing, and neuronal vulnerability in Parkinson's disease. Lancet Neurol. 2007;6:933–938. [PubMed]
201. Svenningsson P, Fienberg AA, Allen PB, Moine CL, Lindskog M, Fisone G, Greengard P, Fredholm BB. Dopamine D(1) receptor-induced gene transcription is modulated by DARPP- 32. J. Neurochem. 2000;75:248–257. [PubMed]
202. Svenningsson P, Fourreau L, Bloch B, Fredholm BB, Gonon F, Le Moine C. Opposite tonic modulation of dopamine and adenosine on c-fos gene expression in striatopallidal neurons. Neuroscience. 1999;89:827–837. [PubMed]
203. Svenningsson P, Le Moine C, Fisone G, Fredholm BB. Distribution biochemistry and function of striatal adenosine A2A receptors. Prog. Neurobiol. 1999;59:355–396. [PubMed]
204. Svenningsson P, Lindskog M, Rognoni F, Fredholm BB, Greengard P, Fisone G. Activation of adenosine A2A and dopamine D1 receptors stimulates cyclic AMP-dependent phosphorylation of DARPP-32 in distinct populations of striatal projection neurons. Neuroscience. 1998;84:223–228. [PubMed]
205. Svenningsson P, Nishi A, Fisone G, Girault JA, Nairn AC, Greengard P. DARPP-32: an integrator of neurotransmission. Annu. Rev. Pharmacol. Toxicol. 2004;44:269–296. [PubMed]
206. Takahashi RN, Pamplona FA, Prediger RD. Adenosine receptor antagonists for cognitive dysfunction: a review of animal studies. Front Biosci. 2008;13:2614–2632. [PubMed]
207. Tanganelli S, Sandager Nielsen K, Ferraro L, Antonelli T, Kehr J, Franco R, Ferre S, Agnati LF, Fuxe K, Scheel-Kruger J. Striatal plasticity at the network level. Focus on adenosine A2A and D2 interactions in models of Parkinson's Disease. Parkinsonism Relat. Disord. 2004;10:273–280. [PubMed]
208. Tebano MT, Martire A, Rebola N, Pepponi R, Domenici MR, Gro MC, Schwarzschild MA, Chen JF, Cunha RA, Popoli P. Adenosine A2A receptors and metabotropic glutamate 5 receptors are co-localized and functionally interact in the hippocampus: a possible key mechanism in the modulation of N-methyl-D-aspartate effects. J. Neurochem. 2005;95:1188–1200. [PubMed]
209. Testa CM, Standaert DG, Young AB, Penney J.B. Jr. Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat. J. Neurosci. 1994;14:3005–3018. [PubMed]
210. Torvinen M, Marcellino D, Canals M, Agnati LF, Lluis C, Franco R, Fuxe K. Adenosine A2A receptor and dopamine D3 receptor interactions: evidence of functional A2A/D3 heteromeric complexes. Mol. Pharmacol. 2005;67:400–407. [PubMed]
211. Tsai SJ, Hong CJ, Hou SJ, Yen FC. Association study of adenosine A2a receptor (1976C>T) genetic polymorphism and mood disorders and age of onset. Psychiatr. Genet. 2006;16:185. [PubMed]
212. Wang JH, Ma YY, van den Buuse M. Improved spatial recognition memory in mice lacking adenosine A2A receptors. Exp. Neurol. 2006;199:438–445. [PubMed]
213. Wang JH, Short J, Ledent C, Lawrence AJ, van den Buuse M. Reduced startle habituation and prepulse inhibition in mice lacking the adenosine A2A receptor. Behav. Brain Res. 2003;143:201–207. [PubMed]
214. Ward RP, Dorsa DM. Molecular and behavioral effects mediated by Gs-coupled adenosine A2a but not serotonin 5-Ht4 or 5-Ht6 receptors following antipsychotic administration. Neuroscience. 1999;89:927–938. [PubMed]
215. Weerts EM, Griffiths RR. The adenosine receptor antagonist CGS15943 reinstates cocaine-seeking behavior and maintains self-administration in baboons. Psychopharmacology (Berl.) 2003;168:155–163. [PubMed]
216. Wirkner K, Gerevich Z, Krause T, Gunther A, Koles L, Schneider D, Norenberg W, Illes P. Adenosine A2A receptor-induced inhibition of NMDA and GABAA receptor-mediated synaptic currents in a subpopulation of rat striatal neurons. Neuropharmacology. 2004;46:994–1007. [PubMed]
217. Woodson JC, Minor TR, Job RF. Inhibition of adenosine deaminase by erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) mimics the effect of inescapable shock on escape learning in rats. Behav. Neurosci. 1998;112:399–409. [PubMed]
218. Yamato T, Yamasaki S, Misumi Y, Kino M, Obata T, Aomine M. Modulation of the stress response by coffee an in vivo microdialysis study of hippocampal serotonin and dopamine levels in rat. Neurosci. Lett. 2002;332:87–90. [PubMed]
219. Yao L, Fan P, Jiang Z, Mailliard WS, Gordon AS, Diamond I. Addicting drugs utilize a synergistic molecular mechanism in common requiring adenosine and Gi-beta gamma dimers. Proc. Natl. Acad. Sci. USA. 2003;100:14379–14384. [PubMed]
220. Yee BK, Singer P, Chen JF, Feldon J, Boison D. Transgenic overexpression of adenosine kinase in brain leads to multiple learning impairments and altered sensitivity to psychomimetic drugs. Eur. J. Neurosci. 2007;26:3237–3252. [PubMed]
221. Zoli M, Agnati LF, Hedlund PB, Li XM, Ferre S, Fuxe K. Receptor-receptor interactions as an integrative mechanism in nerve cells. Mol. Neurobiol. 1993;7:293–334. [PubMed]

Articles from Current Neuropharmacology are provided here courtesy of Bentham Science Publishers